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Introduction: Vaccines require continuous monitoring to increase their 
compliance, quality, and safety. We conducted this study to fulfill the 
research gap for the adverse events following immunization (AEFIs) after 
COVISHIED (ChAdOx1nCoV-19) vaccination among Nepali of eastern 
Nepal. 
 
Method: A cross-sectional study was conducted from 25 Jan 2021 to Jul 
2021 at Birat Medical College Teaching Hospital of Morang, Nepal.  The 
data on COVISHIELD vaccine recipients at this center were analyzed for 
AEFI. Ethical clearance was obtained. 
 
Result: Out of 167 vaccine recipients, the mean age was 28.08±7.35 y. 
The AEFI occurred in 122(73.1%) and 89(72.9%) who developed 
symptoms on the same day of vaccination. The AEFI symptoms were less 
common in males (OR 0.43; CI (0.19-0.96; P 0.03). In both sexes, the AEFI 
symptoms were reported on the same day of vaccination than the next 
day but it had no significant association.  
 
Conclusion: The AEFI following COVISHIED vaccination was reported by 
2/3rd recipients mostly on the same day of the vaccine and less common 
in males.  
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The novel Corona Virus disease 2019 (COVID-
19) pandemic has affected all the countries in 
the world.1 The post-authorization safety 
profile, adverse events following 
immunization (AEFIs), and adverse events of 
special interest (AESIs) are important for 
surveillance, and response of vaccines.2,3 The 
AEFI  after COVISHIELD vaccination was 
reported during its vaccine trial.4  Study found 
AEFI symptoms reported were related to 
vaccine reactogenicity which is mediated by 
pyrogenic cytokines such as interleukin-1 (IL-
1), IL-6, prostaglandin-E2, and tumor necrosis 
factor-alpha (TNF-α), which is released due to 
activation of immune response after 
vaccination.5  
 
Even after approval and licensing of vaccine 
after phase V, the regulatory authorities 
continuously monitor the potency, safety, and 
purity of the vaccine through the vaccine 
adverse event reporting system (VAERS).6,7 
Nepal government has already started 
vaccination of high-risk population with 
COVISHIELD (ChAdOx1nCoV-19) vaccine 
manufactured in India.4,8  
 
We did this study to assess the adverse event 
following COVID-19 vaccination among the 





A cross-sectional study was conducted from 
25 Jan 2021 to 25 Jul 2021 at Birat Medical 
College Teaching Hospital of Morang, Nepal.  
We enrolled 167 COVISHIELD vaccine 
recipients at our center through the census 
enumeration technique. Ethical clearance was 
obtained from the institutional review 
committee of Birat Medical College Teaching 
Hospital. Written informed consent was taken 
from each participant. COVISHIELD is a 
recombinant ChAdOx1 nCoV- 19 Corona Virus 
Vaccine. It is indicated for active 
immunization of individuals ≥18 y old for the 
prevention of coronavirus disease 2019 
(COVID-19).4 As per the serum institute of 
India, common AEFI were categorized as “Very 
common (may affect more than 1 in 10 
people) - tenderness, pain, warmth, or itching 
where the injection is given, generally feeling 
unwell, feeling tired (fatigue), chills or feeling 
feverish, headache, feeling sick (nausea), joint 
pain or muscle ache; Common (may affect 
more than 1 in 10 people) - swelling or 
redness where the injection is given, fever, 
being sick (vomiting) or diarrhea, pain in legs 
or arms, flu-like symptoms, such as high 
temperature sore throat, runny nose, cough 
and chills; Uncommon (may affect up to 1 in 
100 people) – sleepiness or feeling dizzy, 
abdominal pain, enlarged lymph nodes, 
excessive sweating, itchy skin, rash or hives; 
Not known (the frequency cannot be 
determined from the available data) -severe 
allergic reaction (anaphylaxis), severe swelling 
of the lips, mouth, throat (which may cause 
difficulty in swallowing or breathing) and  
Rarest: Major blood clotting (venous and/or 
arterial thrombosis) in combination with low 
platelet count (thrombocytopenia) have been 
observed very rarely (with a frequency less 
than 1 in 100,000 vaccinated individuals)”.4   
 
Most of the adverse events following 
COVISHIELD vaccination occur on the same 
day within 6-8 h and may resolve within 2 to 3 
d and uncommon within a week.4 A 
specifically designed pro forma was used to 
collect data on AEFI. Pro forma contains socio-
demography, symptoms of adverse events, 
the status of previous COVID-19 infection. We 
asked individual participants regarding 
adverse events after having COVISHIELD and 
followed up till 7 d of vaccination. We 
monitored all the possible adverse events 
suggested by the serum institute of India and 
any new events as well by meeting the 
concerned person and also using a phone call. 
Investigators themselves are involved in the 
process of adverse event recording and 
follow-up.  The completeness of the data was 
checked every day. The confidentiality and 
anonymity of data were maintained. The 
collected data was entered in Microsoft Excel 
2016 and analyzed by SPSS version 23. The 
univariate analysis percentage, mean and 
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analysis, the chi-square test and Fischer's 
exact test were used. The statistical 






The mean and standard deviation of the age 
were 28.08 y and 7.35 y respectively. The 
maximum number of participants, 83 (49.7%) 













Mean± SD  28.08±7.35 
Sex  
Female  136(81.4%) 





Department   
Emergency 11(6.6%) 
Intensive Care Unit 72(43.1%) 
Medicine 11 (6.6%) 
Obstetrics & Gynaecology 10(6.0%) 





History of COVID 19  
Yes 38(22.8%) 
No 129(77.2%) 
Date of vaccination  
28 Jan 2021 33(19.8%) 
29 Jan 2021 82(49.1%) 
30 Jan 2021 28(16.8%) 
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Presence of symptoms  
Yes 122(73.1%) 
No 45(26.9%) 
The onset of symptoms  (N=122)  
Same day 89(72.9%) 
Next day 33(27.1%) 








Mean± SD 2.48± 1.42 





Pain at Injection Site 18(10.8%) 
Nausea 14(8.4%) 




Joint Pain  5(3.0%) 
Swelling at Injection site  4(2.4) 
Back Pain 2(1.2%) 
Leg Pain  2(1.2%) 




Table 3.  Association of sex with history of COVID-19 (N=167) 
 
 
Sex History of COVID-19  
OR (CI)  
 
p-value Yes No 
Males  6(19.4%) 25(80.6%) 0.78(0.29-2.07) 0.62 




There were more female participants 
136(81.4%). We had nurses 52(31.1%), 
doctors 14(8.4%), and the remaining 
101(60.5%) were from different sections of 
the hospital. The maximum number of 
participants working at the intensive care unit 
was 72(43.1%). Among them, 38(22.8%) had a 
history of COVID-19 infection.  The majority 
got vaccination on the second day of the 
vaccination program rolled out in the first 
phase of vaccination 82(49.1%), Table 1. 
The maximum number of participants 
122(73.1%) had at least one symptom of AEFI. 
The majority 89(72.9%) developed those 
symptoms within the same day of vaccination. 
The maximum number of participants 
36(29.5%) had at least one symptom followed 
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Table 4. Association of sex with AEFI symptoms (N=167) 
 
 
 Sex OR (CI) p-value 
Male Female 
AEFI Symptoms (Yes) 18(58.1%) 104(76.5%) 0.43(0.19-0.96 0.03* 
Fever (Yes) 12(38.7%) 83(61%) 0.40(0.18-0.90) 0.02* 
Headache (Yes) 2(6.5%) 39(28.7%) 0.17(0.34-0.75) 0.01* 
Body ache (Yes) 6 (19.4%) 34 (25%) 0.72(0.27-1.9) 0.51 
Dizziness (Yes) 0 6(4.4%) NA 0.59# 
Nausea (Yes) 4(12.9%) 10(7.4%) 1.87(0.55-6.4) 0.30# 
Vomiting (Yes) 4(12.9%) 10(7.4%) 1.87(0.55-6.4) 0.30# 
Chills (Yes) 5(16.1%) 7(5.1%) 3.54(1.04-12.04) 0.04#* 
Pain at Injection site (Yes)   2(6.5%) 16(11.8%) 0.56(0.11-2.38) 0.53# 
Swelling at the Injection site (Yes) 0 4(2.9%) 1.03(1-1.06) 1# 
Joint pain (Yes) 1(3.2%) 4(2.9%) 1.1(0.12-10.19) 1# 
Weakness (Yes) 1(3.2%) 11(8.1%) 0.38(0.05-3.05) 0.69# 
SOB (Yes) 0 1(0.7%) 1.01(0.99-1.02) 1# 
Back pain (Yes) 0 2(1.5%) 1.02(0.99-1.04) 1# 
Leg Pain (Yes) 0 2(1.5%) 1.02(0.99-1.04) 1# 
Rigors (Yes) 4(12.9%) 25(18.4%) 0.66(0.21-2.05) 0.47 
Malaise (Yes) 0 1(0.7%) 1.01(0.99-1.02) 1# 
#Fischer’s exact Test *Statistically significant  
 
Table 5. Association of sex with the onset of AEFI symptoms (N=122) 
 
 
Sex Onset of symptoms OR (CI)  p-value 
Same day Next day 
Male  13 (72.2%) 5 (27.8%) 0.96 (0.31-2.93) 1# 
Female 76 (73.1%) 28 (26.9%) 
#Fischer’s Exact Test   
 
Table 6. Association of sex with AEFI symptoms (n=167) 
 
 
 History of COVID-19 OR (CI) p-value 
Yes No 
AEFI Symptoms (Yes) 28(73.7%) 94(72.9%) 1.04(0.46-2.37) 0.92 
Fever (Yes) 22(57.9%) 73(56.6%) 1.06(0.51-2.19) 0.89 
Headache (Yes) 12(31.6%) 29(22.5%) 1.59(0.72-3.54) 0.25 
Body ache (Yes) 12(31.6%) 28(21.7%) 1.67(0.75-3.71) 0.21 
Dizziness (Yes) 0 6(4.7%) 1.05(1.01-1.09) 0.34# 
Nausea (Yes) 4(10.5%) 10(7.8%) 1.4(0.41-4.75) 0.53# 
Vomiting (Yes) 2(5.3%) 12(9.3%) 0.54(0.12-2.53) 0.74# 
Chills (Yes) 3(7.9%) 9(7%) 1.14(0.29-4.45) 1# 
Pain at Injection site (Yes)   3(7.9%) 1(11.6%) 0.65(0.18-2.38) 0.77# 
Swelling at the Injection site 
(Yes) 
1(2.6%) 3(2.3%) 1.14(0.12-11.24) 1# 
Joint pain (Yes) 1(2.6%) 4(3.1%) 0.85(0.93-0.79) 1# 
Weakness (Yes) 4(10.5%) 8(6.2%) 1.78(0.51-6.27) 0.47# 
SOB (Yes) 0 1(0.8%) 1.01(0.99-1.02) 1# 
Back pain (Yes) 1(2.6%) 1(0.8%) 3.46(0.21-56.65) 0.4# 
Leg Pain (Yes) 0 2(1.6%) 1.02(0.99-1.04) 1# 
Rigors (Yes) 8(21.1%) 21(16.3%) 1.37(0.55-3.40) 0.5# 
Malaise (Yes) 0 1(0.8%) 1.01(0.99-1.02) 1# 
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The most common symptoms reported were 
fever 95(56.9%), headache 41(24.6%), Table 2. 
 
History of covid-19 was more in females 
compared to males but there was no 
significant association Table 3. 
 
Sex had a significant association with AEFI 
symptoms which is less common in males (OR 
0.43; CI 0.19-0.96; P 0.03). Further analysis 
found sex had a significant association with 
fever, headache, and chills (table 4). The p-
value is used for the comparison of yes and no 
of each symptom with the sex of the 
participant. 
 
AEFI symptoms were reported more on the 
same day of vaccination in both sex but there 
was no statistically significant difference, 
Table 5.  
 
The history of COVID-19 has no significant 
association with AEFI symptoms. It has no 
further association with each symptom, Table 
6. The p-value is used for the comparison of 
yes and no of each symptom with the history 





We found almost half (49.1%) received the 
COVISHIED vaccine on the second day of the 
first vaccine rollout in this health center. That 
might be due to hesitation to take vaccination 
on the first day because of different rumors 
related to vaccination.9-11 In our study, more 
than one-fifth (22.8%) had a history of COVID-
19 infection. It is similar to a study from 
central Nepal (20.2%).12 Both studies from 
India reported a lower prevalence of history 
of COVID-19 infection than our study, which 
was 7.0%13 and 6.4%5.  
 
We found at least one adverse event 
following COVISHIELD vaccination (73.1%) 
where the majority (81.4%) were female 
health workers in our study. The female 
participants were more because more nursing 
professionals were vaccinated in the first 
phase. Other studies reported 85.04%,12 
91.6%14, 57.24%15 and 40%13 AEFI after 
COVISHIELD vaccination. These findings vary 
in the higher and lower range compared to 
what we found. The possibilities of subjective 
variation in symptom reporting cannot be 
excluded in these studies We need to 
cautiously interpret the findings.  
 
We found almost three-fourth (72.9%) 
reported AEFI symptoms within the same day. 
A study from another sentinel site of central 
Nepal reported 84.4% had onset of symptoms 
within 24 h.12 Both these studies had similar 
findings. More AEFI symptoms on the day of 
vaccination were also suggested by the 
vaccine manufacturer during their vaccine 
trial.4 This is also supported by another phase 
2/3 clinical trials.16 This might be immediate 
vaccine reactogenicity within the same day of 
vaccination.  
 
We found 29.5% had at least one symptom 
followed by two (27.9%) symptoms. A study 
from another sentinel site of central Nepal 
reported an almost similar finding where 
25.6% males and 19.4% females had one 
symptom.12 
 
More than half of the participants had a fever 
as a major symptom in our study.  Other 
symptoms experienced were headache, body 
ache, rigors, pain at the injection site 
respectively from our study participants.  A 
study from another sentinel site of central 
Nepal reported pain at the injection site (55%)  
followed by fever (37.1%), myalgia (30.1%), 
lethargy (27.6%), and headache (26.3%).12 
Another study also reported pain at the 
injection site, weakness, fever, headache, 
joint/muscle pain as major AEFI symptoms.14  
Further another study found fever, headache, 
and dizziness were the commonly reported 
AEFIs, seen respectively in 15.2%, 6.2%, and 
3.7% individuals.13 Other studies found feeling 
unwell (19%), headache (17.4%), fever 
(12.5%), fatigue (12.3%), and muscle ache 
(11.2%).17,18 Solicited injection-site pain was 
the most common local reaction, and fatigue 
and headache were the most common 
systemic reactions.18 Reporting rates of 
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observational studies were similar to results 
from clinical trials.18 Other studies also 
reported a similar type of AEFI symptoms.19 
 
In this study, more females had a history of 
COVID-19 infection but sex has no significant 
association with the history of COVID-19 
within this study population. It means COVID-
19 transmission has no sex preference.  We 
found sex had a significant association with 
AEFI symptoms which is less common in males 
in our bivariate analysis. This association is 
not proved by the causal hypothesis. We need 
further research with an appropriate method. 
Further analysis also found sex had a 
significant association with fever, headache, 
chills. A study from another sentinel site of 
central Nepal reported no statistically 
significant difference in the percentage of 
AEFI seen between males and females.12 
Similar to our study, another study found age 
and gender had a significant effect on AEFI 
severity.14 Similarly, female gender, 
hypothyroid status, and history of allergy 
were observed as significant predictors of 
high risk of AEFI occurrence.10  In our further 
analysis, we found AEFI symptoms were 
reported more on the same day of vaccination 
in both sexes but there was no statistically 
significant difference.  It means a day of onset 
of AEFI has no preferences over the sex of 
study participants. We found the history of 
COVID-19 has no significant association with 
AEFI symptoms. A study from another sentinel 
site of central Nepal reported a similar 
result.12 This study found no significant 
association of the history of COVID-19 with 
each symptom of AEFI. In contrast, a study 
from central Nepal found AEFIs like chills, 
dizziness, running nose, cough, and abdominal 
pain were observed more frequently in the 
COVID group and the difference was 
statistically significant.12  
 
The findings from this study may help health 
experts in formulating plans and policies to 
improve the vaccine response in the mass 
vaccination campaigns against COVID-19. The 
reactogenicity of the vaccine products of 
different companies with different ethnic 
groups or populations might change the 
occurrence of the number and severity of AEFI 
symptoms. We had no encounter with severe 
AEFI but continuous vigilance should be taken 
for the possibilities. In line with other 
studies20 AEFI reported in our study were mild 
and self-resolving resulting in good vaccine 
safety of COVISHIED.  It was suggested to do 
further research on the issue of more AEFI in 
women and young age.21 Because vaccine 
hesitancy in women is the challenge for 
effective vaccination programs.22 We 
recommend strict monitoring of AEFI after 
vaccination. A multicentric study on this 
research question is recommended. Further, 
systematic review and meta-analysis would be 
a great help to conclude.  
 
We are limited not to include some variables 
such as underlying chronic illnesses, smoking 
status, alcohol use, use of tobacco, and 
history of allergies. There might be a 
subjective variation in the symptoms 
reporting. As our study participants have no 
elderly population, this might restrict the 





At least one adverse event following 
COVISHIED vaccination was reported by 2/3rd 
recipients. The AEFI was more in females but 
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